The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology
| Autor: | Chiara Viganò, Gianmichele Meucci, Simone Saibeni, Claudio Papi, Cristina Bezzio, Federica Fascì-Spurio |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Budesonide
medicine.medical_specialty Chronic condition Polymers Drug Compounding Anti-Inflammatory Agents Medication Adherence 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Mesalazine Gastrointestinal Agents medicine Humans Intensive care medicine Mesalamine Drug Carriers Hepatology business.industry Remission Induction Gastroenterology medicine.disease Ulcerative colitis Treatment Outcome chemistry 030220 oncology & carcinogenesis Delayed-Action Preparations Physical therapy 030211 gastroenterology & hepatology Colitis Ulcerative Drug Therapy Combination business medicine.drug MMX |
| Zdroj: | Expert review of gastroenterologyhepatology. 11(1) |
| ISSN: | 1747-4132 |
| Popis: | Ulcerative colitis (uc) is a chronic condition and for the vast majority of patients, life-long treatment is required. low adherence to therapy is an emerging issue. since low adherence is associated with poor clinical outcomes and increased costs, it is becoming crucial to identify strategies in order to improve it. Areas covered: We performed literature searches in PubMed using the terms 'adherence', 'mesalamine', 'budesonide MMX', 'MMX technology' in combination with 'ulcerative colitis'. Firstly, we present the key-concepts of therapy for UC and discuss the problem of the adherence and how to measure it. Then, we provide data on the extent of the problem and the causes and consequences from clinical and economic point of views. Finally, we focus on treatment-related variables associated with non-adherence and treatment-related strategies to improve adherence, paying particular attention to Multi Matrix system (MMX) technology applied to mesalazine and budesonide. Expert commentary: The pharmaceutical industry and scientific community are making efforts to simplify treatments for UC. MMX technology, which allows a reduction in the number of pills to be taken and daily administrations, may facilitate adherence to treatment and carry further clinical benefits. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|